Reflecting this more recent knowledge, the COG’s current phase III clinical trial (AAML1831) includes children with newly diagnosed FLT3-mutated AML and defines FLT3-ITD as any AR greater than 0.1 (NCT04293562) [60]. The gene discussed is FLT3; the disease is acute myeloid leukemia.